Blockade of fatty acid oxidation mimics phase II-phase III transition in a fasting bird, the king penguin.
This study tests the hypothesis that the metabolic and endocrine shift characterizing the phase II-phase III transition during prolonged fasting is related to a decrease in fatty acid (FA) oxidation. Changes in plasma concentrations of various metabolites and hormones and in lipolytic fluxes, as determined by continuous infusion of [2-(3)H]glycerol and [1-(14)C]palmitate, were examined in vivo in spontaneously fasting king penguins in the phase II status (large fat stores, protein sparing) before, during, and after treatment with mercaptoacetate (MA), an inhibitor of FA oxidation. MA induced a 7-fold decrease in plasma beta-hydroxybutyrate and a 2- to 2.5-fold increase in plasma nonesterified fatty acids (NEFA), glycerol, and triacylglycerols. MA also stimulated lipolytic fluxes, increasing the rate of appearance of NEFA and glycerol by 60-90%. This stimulation might be partly mediated by a doubling of circulating glucagon, with plasma insulin remaining unchanged. Plasma glucose level was unaffected by MA treatment. Plasma uric acid increased 4-fold, indicating a marked acceleration of body protein breakdown, possibly mediated by a 2.5-fold increase in circulating corticosterone. Strong similarities between these changes and those observed at the phase II-phase III transition in fasting penguins support the view that entrance into phase III, and especially the end of protein sparing, is related to decreased FA oxidation, rather than reduced NEFA availability. MA could be therefore a useful tool for understanding mechanisms underlying the phase II-phase III transition in spontaneously fasting birds and the associated stimulation of feeding behavior.
Bernard
Servane F
SF
Centre d'Ecologie et Physiologie Energétiques, Centre National de la Recherche Scientifique, 23 rue Becquerel, 67087 Strasbourg, France.
Mioskowski
Eliane
E
Groscolas
René
R
D020155:3-Hydroxybutyric Acid / Q000097:blood; D000818:Animals; D001717:Birds / Q000097:blood / Q000502:physiology*; D005215:Fasting / Q000502:physiology*; D005227:Fatty Acids / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005990:Glycerol / Q000097:blood; D006728:Hormones / Q000097:blood; D007700:Kinetics; D008297:Male; D010084:Oxidation-Reduction / Q000187:drug effects; D013864:Thioglycolates / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D005227:Fatty Acids; D005230:Fatty Acids, Nonesterified; D006728:Hormones; D013864:Thioglycolates; D014280:Triglycerides; D014527:Uric Acid; C017487:2-mercaptoacetate; D005990:Glycerol; D020155:3-Hydroxybutyric Acid